Table 3.
Univariate and multivariable analysis of OS and RFS in oropharyngeal and non-oropharyngeal patients
| Overall survival | Recurrence free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Univariate, HR (95 % CI) | p value* | Multivariable, HR (95 % CI) | p value** | Univariate, HR (95 % CI) | p value* | Multivariable, HR (95 % CI) | p value** |
| Oropharyngeal patients (n = 76)a | ||||||||
| Age (continuous) | 1.07 (1.01-1.12) | 0.03 | 1.03 (0.97-1.10) | 0.3 | 1.05 (1.00-1.10) | 0.08 | 1.02 (0.97-1.08) | 0.4 |
| Sex (males vs females) | No females died | No females had recurrence | ||||||
| ECOG PS (0 vs 1–2) | 4.08 (1.38-12.12) | <0.01 | 4.36 (1.18-16.06) | 0.03 | 3.33 (1.24-8.89) | 0.01 | 2.92 (0.95-8.97) | 0.07 |
| Smoking status | <0.01 | 0.2 | 0.03 | 0.3 | ||||
| (current smokerb vs non-smoker) | 0.17 (0.04-0.70) | 0.34 (0.07-1.64) | 0.31 (0.01-0.98) | 0.53 (0.15-1.88) | ||||
| (current smokerb vs ex-smoker) | 0.22 (0.07-0.80) | 0.28 (0.07-1.09) | 0.28 (0.09-0.85) | 0.40 (0.12-1.31) | ||||
| AJCC stage (I-II vs III-IV) | 0.78 (0.26-2.34) | 0.7 | - | 0.82 (0.31-2.19) | 0.7 | - | ||
| Treatment (CRT and CRT + surgery vs RT and RT + surgery) | 0.50 (0.46-4.93) | 0.5 | - | 0.63 (0.32-4.00) | 0.6 | - | ||
| NLR (≤5 vs > 5) | 4.96 (1.66-14.80) | <0.01 | 4.60 (1.26-16.80) | 0.02 | 3.50 (1.38-8.90) | <0.01 | 3.01 (1.07-8.45) | 0.04 |
| Non-oropharyngeal patients (n = 69)c | ||||||||
| Age (continuous) | 1.02 (0.99-1.06) | 0.8 | - | 1.01 (0.98-1.032) | 0.9 | - | ||
| Sex (males vs females) | 1.05 (0.38-2.87) | 0.9 | - | 0.81 (0.33-1.96) | 0.6 | - | ||
| ECOG PS (0 vs 1–2) | 3.37 (1.36-8.37) | <0.01 | 2.57 (0.98-6.76) | 0.04 | 1.66 (0.82-3.36) | 0.2 | 1.49 (0.70-3.21) | 0.2 |
| Smoking status | 0.04 | <0.001 | 0.02 | <0.001 | ||||
| (current smokerb vs non-smoker) | 0.18 (0.04-0.79) | 0.16 (0.03-0.76) | 0.35 (0.14-0.87) | 0.35 (0.14-0.90) | ||||
| (current smokerb vs ex-smoker) | 0.56 (0.22-1.44) | 0.34 (0.12-0.94) | 0.38 (0.16-0.90) | 0.32 (0.13-0.79) | ||||
| AJCC stage (I-II vs III-IV) | 1.43 (0.56-3.70) | 0.5 | - | 1.53 (0.68-3.42) | 0.3 | - | ||
| Treatment (CRT and CRT + surgery vs RT and RT + surgery) | 0.85 (0.46-2.57) | 0.8 | - | 1.01 (0.50-2.05) | 1 | - | ||
| NLR (≤5 vs > 5) | 3.32 (1.36-8.10) | <0.01 | 3.64 (1.34-9.87) | 0.02 | 1.76 (0.79-3.96) | 0.2 | 2.02 (0.83-4.91) | 0.1 |
Abbreviations: HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer, CRT chemoradiotherapy, RT radiotherapy and NLR neutrophil-to-lymphocyte ratio
*, p value from Kaplan-Meier logrank test; **, p value from Cox regression log likelihood ratio test; a, one patient missing smoking status; b, referent group; and c, missing 3 patients (two patients missing smoking status and one patient missing ECOG status).